Dustin Osborne, Cathy S Cutler, Ivis F Chaple, Patrícia M Ribeiro Pereira, Todd E Peterson, Kiran K Solingapuram Sai, Jiaqiong Wang, Peter J H Scott, Delphine L Chen
{"title":"Industry-Academic Collaboration in Nuclear Medicine: Proceedings from the 2024 CMIIT Industry Partners Circle.","authors":"Dustin Osborne, Cathy S Cutler, Ivis F Chaple, Patrícia M Ribeiro Pereira, Todd E Peterson, Kiran K Solingapuram Sai, Jiaqiong Wang, Peter J H Scott, Delphine L Chen","doi":"10.2967/jnumed.126.272619","DOIUrl":null,"url":null,"abstract":"<p><p>Advancing and streamlining the development pipeline and translation of theranostic radiopharmaceuticals for application in nuclear medicine necessitates continued cross-sector collaboration among key stakeholders from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), industry partners, and academics to ensure continued growth and innovation and clinical translation. One mechanism the SNMMI has for such dialogue is its biennial Industry Partners Circle (IPC). After the success of prior IPCs, the Center for Molecular Imaging, Innovation, and Translation (CMIIT) hosted the latest IPC in January 2024. The goals of the 2024 CMIIT IPC were to address 4 key priorities that have emerged for the translational community: grow the workforce pipeline, improve academia/industry collaborations to support career development, facilitate radiopharmaceutical clinical trials, and overcome barriers in developing α-therapies. The IPC was attended by SNMMI staff and leadership, members of the CMIIT board of directors, key stakeholders from academia, and industry representatives from a broad range of biopharmaceutical companies and equipment manufacturers. This article summarizes the discussions that were conveyed at the 2024 CMIIT IPC.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1365-1368"},"PeriodicalIF":9.1000,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.126.272619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Advancing and streamlining the development pipeline and translation of theranostic radiopharmaceuticals for application in nuclear medicine necessitates continued cross-sector collaboration among key stakeholders from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), industry partners, and academics to ensure continued growth and innovation and clinical translation. One mechanism the SNMMI has for such dialogue is its biennial Industry Partners Circle (IPC). After the success of prior IPCs, the Center for Molecular Imaging, Innovation, and Translation (CMIIT) hosted the latest IPC in January 2024. The goals of the 2024 CMIIT IPC were to address 4 key priorities that have emerged for the translational community: grow the workforce pipeline, improve academia/industry collaborations to support career development, facilitate radiopharmaceutical clinical trials, and overcome barriers in developing α-therapies. The IPC was attended by SNMMI staff and leadership, members of the CMIIT board of directors, key stakeholders from academia, and industry representatives from a broad range of biopharmaceutical companies and equipment manufacturers. This article summarizes the discussions that were conveyed at the 2024 CMIIT IPC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
